Perspective Therapeutics: A Buy Rating for the Next-Gen Radiopharmaceutical Leader

BTIG analyst sees Perspective Therapeutics as "next-gen radiopharmaceutical leader" with strong competitive advantages and upcoming catalysts through 2026.